Literature DB >> 10911925

Development of novel medications for drug addiction. The legacy of an African shrub.

S D Glick1, I M Maisonneuve.   

Abstract

Ibogaine, one of several alkaloids found in the root bark of the African shrub Tabernanthe iboga, has been claimed to be effective in treating multiple forms of drug abuse. Problems associated with side effects of ibogaine have spawned a search for more effective and safer structural derivatives. 18-Methoxycoronaridine (18-MC), a novel iboga alkaloid congener, appears to have substantial potential for broad use as an anti-addictive therapy. Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; unlike ibogaine, 18-MC does not affect responding for a non-drug reinforcer (water). Ibogaine and 18-MC appear to reduce the reinforcing efficacies, rather than the potencies, of drugs of abuse. Both ibogaine and 18-MC decreases extracellular levels of dopamine in the nucleus accumbens while only ibogaine increases serotonin levels in this brain region. Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the accumbens; only ibogaine enhances cocaine-induced increases in dopamine levels. Ibogaine produces whole body tremors and, at high doses (at least 100 mg/kg), cerebellar damage; 18-MC does not produce these effects. Ibogaine, but not 18-MC, causes bradycardia at high doses. Ibogaine and its metabolite noribogaine have low microM affinities for kappa and mu opioid receptors, NMDA receptors, 5HT-3 receptors, sigma-2 sites, sodium channels and the serotonin transporter. 18-MC has low microM affinities at all three opioid receptors and at 5HT-3 receptors but much lower or no affinities for NMDA and sigma-2 receptors, sodium channels, and the 5HT transporter. Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 18-MC also has (+) and (-) enantiomers, both of which are active. Considered together, all of the data indicate that 18-MC should be safer than ibogaine and at least as efficacious as an anti-addictive medication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10911925     DOI: 10.1111/j.1749-6632.2000.tb06677.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

Review 1.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

Review 2.  Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.

Authors:  S Chatterjee; S E Bartlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

3.  Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Authors:  Dao-Yao He; Nancy N H McGough; Ajay Ravindranathan; Jerome Jeanblanc; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

Review 4.  The role of nicotinic acetylcholine receptors in alcohol-related behaviors.

Authors:  C N Miller; H M Kamens
Journal:  Brain Res Bull       Date:  2020-07-22       Impact factor: 4.077

5.  AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology.

Authors:  Andrea Cippitelli; Jinhua Wu; Kelly A Gaiolini; Daniela Mercatelli; Jennifer Schoch; Michelle Gorman; Alejandra Ramirez; Roberto Ciccocioppo; Taline V Khroyan; Dennis Yasuda; Nurulain T Zaveri; Conrado Pascual; Xinmin Simon Xie; Lawrence Toll
Journal:  Br J Pharmacol       Date:  2015-01-23       Impact factor: 8.739

6.  Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice.

Authors:  Jian-feng SUN; Yu-hua WANG; Fu-ying LI; Gang LU; Yi-min TAO; Yun CHENG; Jie CHEN; Xue-jun XU; Zhi-qiang CHI; John L NEUMEYER; Ao ZHANG; Jing-gen LIU
Journal:  Acta Pharmacol Sin       Date:  2010-11-22       Impact factor: 6.150

7.  [¹²⁵I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors.

Authors:  Jinhua Wu; David C Perry; James E Bupp; Faming Jiang; Willma E Polgar; Lawrence Toll; Nurulain T Zaveri
Journal:  Neuropharmacology       Date:  2013-10-03       Impact factor: 5.250

Review 8.  GDNF--a potential target to treat addiction.

Authors:  Sebastien Carnicella; Dorit Ron
Journal:  Pharmacol Ther       Date:  2008-12-24       Impact factor: 12.310

Review 9.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

10.  Salviae Miltiorrhizae BGE Radix increases rat striatal K(+)-stimulated dopamine release and activates the dopamine release with protection against hydrogen peroxide-induced injury in rat pheochromocytoma PC12 cells.

Authors:  Tae-Wook Chung; Byung-Soo Koo; Kyeong-Oh Kim; Hee-Sang Jeong; Min-Gon Kim; Kang-Hung Chung; In-Seon Lee; Cheorl-Ho Kim
Journal:  Neurochem Res       Date:  2006-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.